Another Shkreli-like drug price controversy? Leadiant finds itself in the spotlight after 500-fold price hike — FT
Martin Shkreli may be cooling his heels in a federal prison, but the pharma pricing strategy he pursued that got him into an intense national …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
